New functional tools for antithrombogenic activity assessment of live surface glycocalyx

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 9, 2016, Pages 1847-1853

  Dimitrievska, Sashka ^a   Gui, Liqiong ^b   Weyers, Amanda ^b,e   Lin, Tylee ^a   Cai, Chao ^e   Wu, Wei ^a   Tuggle, Charles T ^b   Sundaram, Sumati ^b   Balestrini, Jenna L ^b   Slattery, David ^d,f   Tchouta, Lise ^c   Kyriakides, Themis R ^a,b   Tarbell, John M ^g   Linhardt, Robert J ^d,e   Niklason, Laura E ^a,b  

^a Yale University   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^f University of Connecticut   (United States)

^g City College of New York   (United States)

Author keywords

Anesthesia; Endothelial cells; Glycocalyx; Heparin; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 10A; GLYCOSAMINOGLYCAN; HEPARIN; THROMBIN; ANTITHROMBIN; HEPARAN SULFATE;

ACCURACY; ANIMAL CELL; ANTICOAGULATION; ANTITHROMBOGENIC ACTIVITY ASSESSMENT; ARTICLE; CONTROLLED STUDY; FUNCTIONAL ASSESSMENT; GLYCOCALYX; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER; MASS SPECTROMETRY; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT; VALIDITY; VASCULAR ENDOTHELIUM; ANIMAL; BIOASSAY; BLOOD CLOTTING; CELL CULTURE; COMPARATIVE STUDY; MALE; METABOLISM; PROCEDURES; REPRODUCIBILITY; SPRAGUE DAWLEY RAT; THORACIC AORTA; TIME FACTOR; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTITHROMBINS; AORTA, THORACIC; BIOLOGICAL ASSAY; BLOOD COAGULATION; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; FACTOR XA; GLYCOCALYX; HEPARIN; HEPARITIN SULFATE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; MALE; MASS SPECTROMETRY; MICROSCOPY, ELECTRON, TRANSMISSION; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; THROMBIN; TIME FACTORS;

EID: 84978141383     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.308023     Document Type: Article

References (26)

1. van den Berg BM, Nieuwdorp M, Stroes ES, Vink H, Glycocalyx and endothelial (dys) function: From mice to men. Pharmacol Rep 2006 suppl 58 75 80
2. Weinbaum S, Tarbell JM, Damiano ER, The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng 2007 9 121 167. doi: 10.1146/annurev.bioeng.9.060906.151959
3. Zeng Y, Ebong EE, Fu BM, Tarbell JM, The structural stability of the endothelial glycocalyx after enzymatic removal of glycosaminoglycans. PLoS One 2012 7 e43168. doi: 10.1371/journal.pone.0043168
4. Woodcock TE, Woodcock TM, Revised Starling equation and the glycocalyx model of transvascular fluid exchange: An improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth 2012 108 384 394. doi: 10.1093/bja/aer515
5. Becker BF, Chappell D, Bruegger D, Annecke T, Jacob M, Therapeutic strategies targeting the endothelial glycocalyx: Acute deficits, but great potential. Cardiovasc Res 2010 87 300 310. doi: 10.1093/cvr/cvq137
6. Potter DR, Jiang J, Damiano ER, The recovery time course of the endothelial cell glycocalyx in vivo and its implications in vitro. Circ Res 2009 104 1318 1325. doi: 10.1161/CIRCRESAHA.108.191585
7. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG, The endothelial glycocalyx: Composition, functions, and visualization. Pflugers Arch 2007 454 345 359. doi: 10.1007/s00424-007-0212-8
8. Kinsella MG, Irvin C, Reidy MA, Wight TN, Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries. Atherosclerosis 2004 175 51 57. doi: 10.1016/j.atherosclerosis.2004.01.045
9. Lindblom A, Fransson LA, Endothelial heparan sulphate: Compositional analysis and comparison of chains from different proteoglycan populations. Glycoconj J 1990 7 545 562
10. Tumova S, Woods A, Couchman JR, Heparan sulfate proteoglycans on the cell surface: Versatile coordinators of cellular functions. Int J Biochem Cell Biol 2000 32 269 288
11. Justus AC, Roussev R, Norcross JL, Faulk WP, Antithrombin binding by human umbilical vein endothelial cells: Effects of exogenous heparin. Thromb Res 1995 79 175 186
12. Shriver Z, Sundaram M, Venkataraman G, Fareed J, Linhardt R, Biemann K, Sasisekharan R, Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. Proc Natl Acad Sci USA 2000 97 10365 10370
13. Dull RO, Mecham I, McJames S, Heparan sulfates mediate pressure-induced increase in lung endothelial hydraulic conductivity via nitric oxide/reactive oxygen species. Am J Physiol Lung Cell Mol Physiol 2007 292 L1452 L1458. doi: 10.1152/ajplung.00376.2006
14. Nieuwdorp M, Meuwese MC, Vink H, Hoekstra JB, Kastelein JJ, Stroes ES, The endothelial glycocalyx: A potential barrier between health and vascular disease. Curr Opin Lipidol 2005 16 507 511
15. Hirsh J, Anand SS, Halperin JL, Fuster V, American Heart Association Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association. Circulation 2001 103 2994 3018
16. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE, Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001 119 suppl 1 64S 94S
17. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Söderström G, Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 1979 15 531 541
18. Hansen JB, Olsen R, Webster P, Association of tissue factor pathway inhibitor with human umbilical vein endothelial cells. Blood 1997 90 3568 3578
19. Kato H, Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: Basic and clinical aspects. Arterioscler Thromb Vasc Biol 2002 22 539 548
20. Peraramelli S, Thomassen S, Heinzmann A, Rosing J, Hackeng TM, Hartmann R, Scheiflinger F, Dockal M, Inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs. J Thromb Haemost 2014 12 1826 1837. doi: 10.1111/jth.12713
21. Dull RO, Dinavahi R, Schwartz L, Humphries DE, Berry D, Sasisekharan R, Garcia JG, Lung endothelial heparan sulfates mediate cationic peptide-induced barrier dysfunction: A new role for the glycocalyx. Am J Physiol Lung Cell Mol Physiol 2003 285 L986 L995. doi: 10.1152/ajplung.00022.2003
22. Scully MF, Ellis V, Kakkar VV, Heparan sulphate with no affinity for antithrombin III and the control of haemostasis. FEBS Lett 1988 241 11 14
23. van Golen RF, Reiniers MJ, Vrisekoop N, Zuurbier CJ, Olthof PB, van Rheenen J, van Gulik TM, Parsons BJ, Heger M, The mechanisms and physiological relevance of glycocalyx degradation in hepatic ischemia/reperfusion injury. Antioxid Redox Signal 2014 21 1098 1118. doi: 10.1089/ars.2013.5751
24. Lipowsky HH, Protease activity and the role of the endothelial glycocalyx in inflammation. Drug Discov Today Dis Models 2011 8 57 62. doi: 10.1016/j.ddmod.2011.05.004
25. Ofosu FA, Modi GJ, Blajchman MA, Buchanan MR, Johnson EA, Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate. Biochem J 1987 248 889 896
26. Bar RS, Dake BL, Spanheimer RG, Sulfated glycosaminoglycans in cultured endothelial cells from capillaries and large vessels of human and bovine origin. Atherosclerosis 1985 56 11 26